Liver transplant for viral hepatitis and fulminant hepatic failure

Minerva Gastroenterologica e Dietologica

Volumn 55, Issue 1, 2009, Pages 83-100

  Mukherjee, S ^a,c   Mahmoudi, T M ^a   Mukherjee, U ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c Section of Gastroenterology and Hepatology   (United States)

Author keywords

Hepatitis; Liver failure; Liver transplantation

Indexed keywords

ACETYLCYSTEINE; ADEFOVIR; AZATHIOPRINE; CYCLOSPORIN; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISONE; RIBAVIRIN; STEROID; TACROLIMUS; TELBIVUDINE; TENOFOVIR;

ACUTE GRAFT REJECTION; AMANITA PHALLOIDES; AUTOIMMUNE HEPATITIS; BRONCHOSPASM; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG INTOXICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT REJECTION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER GRAFT; LIVER TOXICITY; LIVER TRANSPLANTATION; META ANALYSIS; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RETRANSPLANTATION; REVIEW; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URTICARIA;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; RECURRENCE;

EID: 67649388535     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER et al. NIH consensus development statement conference on management of hepatitis B. NIH Consensus State Sci Statements 2008[Epub ahead of print].
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone from a blood-borne, non A-non B viral hepatitis genome. Science 1989;244:359-62.
3. Gane EG, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT et al. Long term outcome of hepatitis C after liver transplantation. N Engl J Med 1996;334:815-20.
4. McCashland TM, Watt K, Lyden E, Adams L, Charlton M, Smith AD, et al. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl 2007; 13:1246-53-
5. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepatitis 2004;ll:97-107.
6. Kim WR, Ishitani MD, Dickson ER. Rising burden of hepatitis B in the United States:should the 'other 'virus be forgotten? Hepatology 2002;36:222A.
7. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.
8. Perrillo RP, Wright T, Rakela J, Levy, Schiff E, Gish R, etal. Lamivudine North American Transplant Group. A multicenter United States Canadian trial to assess lamivudine monotherapy before and after liver transplantation. Hepatology 2001;33:424-32.
9. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality on patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719-27.
10. Grellier L, Multimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-5.
11. Perillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999;29:1581-6.
12. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M et al. Adefovir dipivoxil therapy for lami-vudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 2003;38:l419-27.
13. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007:13:349-60.
14. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-9.
15. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple -resistant hepatitis B virus strain in a liver transplanted patient. Gastroenterology 2006;131:1253-6l.
16. Ratziu V, Thibault V, Benhamou Y, Poynard T. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Compar hepatol 2OO6;5:l.
17. Choe WH, Kwon SY, Kim BK, Ko SY, Yeon JE, Byun KS, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients. Liver Int 2008;28:814-20.
18. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997;64:1582-4.
19. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B etal. Antibodies to hepatitis B surface antigen prevent reactivation in recipients of liver grafts from anti-Hb core anti-HB c positive donors. Gut 2002;50:95-9.
20. Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137:572-5.
21. Davies SE, Portmann BC, OGrady JG, Aldis PM, Chaggar K, Alexander GJ et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection , including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-7.
22. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ. Starzl TE. Orthotopic liver transplantation for hepatitis B-virus related liver disease. Hepatology 1991;6l9-26.
23. O'Grady JG, Smith HM, Davies SE. Daniels HM, Donaldson PT, Tan KC et al. Hepatitis B virus infection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104-ll.
24. Muller R, Gubernatis G, Fade M, Niehoff G, Klein H. Wittekind C et al. Liver transplantation in HBs antigen carriers. Prevention of hepatitis B virus recurrence by passive immunization. J Hepatol 1991;13:90-6.
25. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl | Med 1993;329:1842-7.
26. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999;30:715-21.
27. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to liver transplantation as a risk factor for reinfection. I Hepatol 20Ol;34:895-902.
28. Marzano A, Salizzoni M, Debernadi-Vernon W, Smedile A, Franchello A, Cianco A et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-10.
29. Seehofer D, Rayes N, Naumann U, Neuhaus R, Muller AR, Tullius SG et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001;72:1381-5.
30. Dan Y, Wai C, Yeoh K, Lim S. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006;12:736-46.
31. Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL. Intramuscular hepatitis B immunoglobulin and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant 2007;21:510-7.
32. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP et al. Lamivudine plus low dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931-7.
33. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460-6
34. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin. Clin Transplant 2006;20:206-10
35. Charlton M, Ruppert K, Belle SH, Bass N, Schafer S, Wiesner RH, etal. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2OO4;1O:112O-3O.
36. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005;ll:479-89.
37. Charlton M, Seaberg E, Wiesner R, Evehart J, Zetterman R, Lake J et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-30.
38. Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999;117:149-53.
39. Wilson S, Mangus RS, Tector AJ, Chalasani N, Kwo P. Use of infected liver donors in liver transplantation: a case-control study. Gastroenterology 2007;132:A728.
40. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA , McDiarmid SV et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:l453-7.
41. Fors X, Garcia-Retortillo , Serano T, Feliu A, Suarez F, de la Mata M et al. Anitiviral therapy of patients with decom-pensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-96.
42. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-62.
43. Martinez-Bauer E, Carrion JA, Ramirez S. Antiviral therapy of patients with decompensated cirrhosis to prevent hepatitis C recurrence after liver transplantation. J Hepatol 2006;44:S64.A150.
44. Davis GL, Nelson DR, Terrault N, Pruett T, Schiano TD, Fletcher CV et al. A randomized, open-label study to evalaute the safety and pharmacokinetics of human hepatitis C immunoglobulin (Civacir) in liver transplant recipients. Liver Transpl 2005;ll:94l-9.
45. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed Al, Hemming AW, Liu C et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplant 2004;10:199-207.
46. Mukherjee S. Fatal liver disease despite sustained eradication of recurrent hepatitis C virus requiring liver retransplantation. Transplantation 2006;82:286-8.
47. Walter T, Dumortier J, Guillaud O, Hervieu V, Paliard P, Scoazec JY et al. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007;7:177-84.
48. Mukherjee S, Ariyarathna K. Successful eradication of recurrent HCV with preservation of renal function in a liver-kidney transplant recipient with pegylated interferon and ribavirin. Transplantation 2007;84:1374-5.
49. Charlton M. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep 2007;9:23-30.
50. Arjal RR, Burton JR Jr, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007;26:127-40.
51. Nakagawa M. Specific inhibition of HCV replication by cyclosporin A. Biophys Res Commun 2004;313:42-7.
52. Berenguer M. Recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transpl 2007;13:64l-3.
53. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J et al A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442-50.
54. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A et al. Influence of steroids on HCV recur- rence after liver transplantation: a prospective study. J Hepatol 2007;47:793-8.
55. Demetris AJ, Eghtesad B, Marcos A, Ruppert K, Nalesnik MA, Randhawa P et al. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls and observations about pathogenesis. Am J Surg Pathol 2004;28:658-69.
56. Mukherjee S, Sorrell MF. Controversies in liver transplantation for hepatitis C. Gastroenterology 2008; 134:1777-88.
57. Lee WM, Squires Jr RH, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology 2008;47:l401-15.
58. O'Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-55.
59. O'Grady JG, Schalm SW, Williams R. Acute liver failu-re:redefining the syndromes. Lancet 1993;342:273-5.
60. Clemmenson JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentrations. Hepatology 1999;29:648-53-
61. Brok J, Buckley N, Gluud C. Interventions for acetaminophen overdose. Cochrane Database Syst Review 2006 April 19;2:CD003328.
62. Sato RL, Wong JJ, Sumida SM, Marn RY, Enoki NR, Yamamoto LG. Efficacy of superactivated charcoal administration late (three hours) after acetaminophen overdose. Am J Emerg Med 2002;21:189-91.
63. Lee WM, Drug-induced heaptotoxicity. N Engl J Med 2003;349:474-85.
64. Harrison PM, Keays R, Bray GP, Alexander GJM, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990;335:1572-3.
65. Ocker S, Brunt EM, Cohn SM, Krul ES, Hanto DW, Peters MG. Fulminant hepatic failure caused by acute fatty liver of pregnancy treated by orthotopic liver transplantation. Hepatology 1990;ll:59-64.
66. Khuroo MS, Kamili S. Aetiology and prognostic factors of acute liver failure in Indai. J Viral Hepatol 2003:10:224-31.
67. Klein AS, Hart J, Brems JJ, Goldstein L, Lewin K, Bussutil RW. Amanita poisoning: treatment and the role of liver transplantation. Am J Med 1989;86:187-93.
68. Enjalbert F, Rapior S, Nougier-Soule J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poiso-ning:20 year retrospective analysis. J Toxicol Clin Toxicol 2002;40:715-57.
69. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liv Dis 2002;22:365-78.
70. Ichai P, Duclos-Vallee J-C, Guettier C, Ben Hamida S, Antonini T, Delvart V et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003.
71. Czaja A. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis:therapeutic brinksman-ship and the point beyond salvation. Liv Transpl 2O07;13:953-5.
72. Roberts EA, Schilsky ML. AASLD Practice guidelines: A practical guideline to Wilson's disease. Hepatology 2003;37:l475-92.
73. KormanJD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH Jr et al. Screening for Wilson's disease in acute liver failure: a comparison of currently available diagnostic tests Pediatric and Adult Acute Liver Failure Study Groups. Hepatology 2008;48:ll67-74.
74. Alba L, Hay J, Angulo P. Lactulose therapy in acute liver failure. J Hepatol 2002;36:33A.
75. Vaquero J, Fontana RJ, Larson AM, Bass NM,Davern TJ, Shakil AO et al. Complications and use of intracra- nial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005;ll:1581-9.
76. Keays RT, Alexander GJ, Williams R. The safety and value of extradural intracranial pressure monitors in fulminant hepatic failure. J Hepatol 1993;18:205-9.
77. Poca MA, Sahuquillo J, Topczewski T, Penarubia MJ, Muns A. Is intracranial pressure monitoring in the epi-dural space reliable? Fact or fiction. J Neurosurg 2007;106:548-56.
78. Ng I, Lim J, Wong HB. Effects of head posture on cerebral hemodynamics: its influences on intracranial pressure, cerebral perfusion pressure and cerebral oxyge-nation. Neurosurgery 2004;54:593-7.
79. Lidofsky SD, Bass NM, Prager MC, Washington DE, Read AE, Wright TL et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 1992;l6:l-7.
80. Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994;19:l407-13-
81. Garcia-Morales EJ, Cariappa R, Parvin CA, Scott MG, Diringer MN. Osmole gap in neurologic-neurosurgi-cal intensive care unit: its normal value, calculation and relationship with mannitol serum concentration. Crit Care Med 2004;32:986-91.
82. Forbes A, Alexander GJ, O'Grady JG, Keays R, Gullan R, Dawling S et al. Thiopental infusion in the treatment of intracranial hypertension complication fulminate hepatic failure. Hepatology 1989; 10:306-10.
83. Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004;127:1338-46.
84. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004;39:464-70.
85. Stravitz R Todd, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta R et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007;35:2498-508.
86. Rolando N, Gimson A, Wade J, Philpott-Howard J, Casewell M, Williams R. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology 1993;17:196-201.
87. Holmes CL. Vasoactive drugs in the intensive care unit. Curr Opin Crit Care 2005; 11:413-7.
88. Harry R, Auzinger G, Wendon J.The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002:36:395-402.
89. The acute respiratory distress syndrome network: ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8.
90. Munoz SJ. Nutritional therapies in liver disease. Semin LivDis 1991:11:278-91.
91. Shah MR, Hasselblad V, Stevenson LW, Binany, O'Connor CM, Sopko G et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA 2005;294:1664-70.
92. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993:21:328-38.
93. Wijdicks EF, Nyberg SL. Propofol to control intracranial pressure in fulminant hepatic failure. Transplant Proc 2002;34:1220-2.
94. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 2005:33:311-22.
95. Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostatis in acute liver failure. Semin Liv Dis 1996; 16:403-14.
96. Porte RJ, Caldwell SH. The role of recombinant factor Vila in liver transplantation. Liver Transpl 2005; 11:872-4.
97. Munoz SJ, Ballas SK, Moritz MJ, Martinez J, Friedman LS. Jarrell BE et al. Periopeative management of fulminant and subfulminant hepatic failure with therapeutic pla-smapheresis. Transplant Proc 1989:21:3535-6.